Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO.

J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.

PMID:
22965953
[PubMed - indexed for MEDLINE]
2.

[Angiogenesis in patients with hematologic malignancies].

Mesters RM, PadrĂ³ T, Steins M, Bieker R, Retzlaff S, Kessler T, Kienast J, Berdel WE.

Onkologie. 2001 Sep;24 Suppl 5:75-80. Review. German.

PMID:
11600818
[PubMed - indexed for MEDLINE]
3.

Targeting mutant p53 in human tumors.

Lehmann BD, Pietenpol JA.

J Clin Oncol. 2012 Oct 10;30(29):3648-50. doi: 10.1200/JCO.2012.44.0412. Epub 2012 Sep 10. Review. No abstract available.

PMID:
22965952
[PubMed - indexed for MEDLINE]
4.

Predicting the effect of transcription therapy in hematologic malignancies.

Melnick A.

Leukemia. 2005 Jul;19(7):1109-17. Review.

PMID:
15858614
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk